BioSpace News Archive

PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy, is pleased to announce the appointment of David Harrison as President of the Americas.

Acasti Pharma Inc. today announced that the Company has aligned with the U.S. Food and Drug Administration (FDA) on the protocol for its pivotal Phase 3 trial of GTX-104 and the FDA also provided guidance for a potential GTX-104 New Drug Application (NDA) package.

Ultromics, a leading health technology company advancing a novel approach for detecting heart failure and its phenotypes, announced today the assignment of a new outpatient code by the Centers for Medicare and Medicaid Services (CMS), for its flagship product, EchoGo® Heart Failure.

Salvia BioElectronics, a pioneering company focused on neuromodulation for severe migraine, announced the successful first implantation of their paper-thin neuromodulation solution.

Evolution Optiks Limited announced today that Prof. Dr. Thomas Neuhann had joined the ranks of experts serving on the Advisory Board of the company.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of seven abstracts in Parkinson’s disease (PD) at the 9th Congress of the European Academy of Neurology (EAN), which was held in Budapest, July 1-3 , and the 6th World Parkinson Congress (WPC), being held in Barcelona, July 4-7.

The Kleine-Levin Syndrome Foundation today announced updated diagnostic criteria for Kleine-Levin Syndrome (KLS) published in the International Classification of Sleep Disorders Third Edition.

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, is set to unveil its “PURE Genius” food safety program at the 2023 International Association for Food Protection (IAFP) show in Toronto, Ontario, Canada on July 16th -19th, 2023.

Propanc Biopharma, Inc. today announced that synthetic recombinant proenzymes trypsinogen and chymotrypsinogen were successfully produced via the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program with the Universities of Jaén and Granada, Spain.

H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share.